Liraglutide and dulaglutide are both GLP-1 receptor agonists, but they differ in a practical way patients feel daily: dosing frequency. Liraglutide is a once-daily injection; dulaglutide is once weekly. They have broadly comparable, modest weight-loss effects compared with newer agents, and both carry cardiovascular outcome data.
At a glance
| Liraglutide | Dulaglutide | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand names | Victoza, Saxenda | Trulicity |
| FDA status | Approved | Approved |
| Dosing frequency | Once daily | Once weekly |
| Weight loss | Modest | Modest |
| Cardiovascular data | LEADER outcomes trial | REWIND outcomes trial |
| Main side effects | GI: nausea, diarrhea | GI: nausea, diarrhea |
The bottom line
Bottom line: The headline difference is convenience — weekly dulaglutide vs daily liraglutide — with both offering modest weight loss and solid cardiovascular outcome data (REWIND and LEADER). Liraglutide also has a dedicated higher-dose weight-management product (Saxenda). Both are established, approved prescription GLP-1 drugs.
Frequently asked questions
Is liraglutide or dulaglutide better?
They are broadly comparable GLP-1 agonists; dulaglutide's once-weekly dosing is more convenient than daily liraglutide, while liraglutide has a dedicated weight-management form (Saxenda). Both have cardiovascular outcome data. The choice is clinical.
What's the dosing difference?
Liraglutide is injected once daily; dulaglutide is injected once weekly. For people who prefer fewer injections, the weekly schedule is often favored.
Do both help with weight loss?
Both produce modest weight loss, less than newer agents like semaglutide or tirzepatide. Liraglutide is specifically approved for weight management as Saxenda.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. Peer-reviewed study
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. Peer-reviewed study
- Guo T, Yan W, Cui X, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. Peer-reviewed study
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. Peer-reviewed study
- Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024. Peer-reviewed study
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020. Peer-reviewed study
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. Peer-reviewed study
- Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in type 2 diabetes: review of the AWARD phase 3 program. Diabetes Metab Res Rev. 2016. Peer-reviewed study
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. Peer-reviewed study
- Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024. Peer-reviewed study
- Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. Peer-reviewed study
- Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. Peer-reviewed study